Expertise in
1
conditions

Dr. Ronald Chochinov

Endocrinology
Ronald H Chochinov MD Inc
168 N Brent St Ste 405, 
Ventura, CA 
Expertise in
1
conditions
Ronald H Chochinov MD Inc
168 N Brent St Ste 405, 
Ventura, CA 

Overview

Ronald Chochinov is an Endocrinologist in Ventura, California. Dr. Chochinov is highly rated in 1 condition, according to our data. His top areas of expertise are Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), Type 1 Diabetes (T1D), and Obesity in Children.

His clinical research consists of participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Endocrinology

Licenses

Internal Medicine in CA

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

Ronald H Chochinov MD Inc
168 N Brent St Ste 405, Ventura, CA 93003

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

12 Clinical Trials

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (SURPASS-CVOT)
Enrollment Status: Completed
Publish Date: August 24, 2025
Intervention Type: Drug
Study Drugs: Tirzepatide, Dulaglutide
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
A Phase 3, Multicenter, Randomized, Parallel-Design, Open-Label Trial to Evaluate the Efficacy and Safety of LY3209590 Compared With Insulin Degludec in Participants With Type 2 Diabetes Currently Treated With Basal Insulin (QWINT-3)
Enrollment Status: Completed
Publish Date: June 03, 2025
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 3
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
A Phase 2 Study of Once-Weekly LY3437943 Compared With Placebo in Participants Who Have Obesity or Are Overweight With Weight-Related Comorbidities
Enrollment Status: Completed
Publish Date: September 13, 2023
Intervention Type: Drug
Study Drug: LY3437943
Study Phase: Phase 2
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
A Study of LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring
Enrollment Status: Completed
Publish Date: March 03, 2023
Intervention Type: Drug
Study Drugs: LY900014, Insulin Glargine
Study Phase: Phase 3
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
A Prospective, Multi-center, Phase 1b/2a Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Association With Teplizumab in Patients With Clinical Recent-onset Type 1 Diabetes Mellitus (T1D)
Enrollment Status: Completed
Publish Date: February 01, 2023
Intervention Type: Biological, Drug
Study Drugs: AG019 - Low Dose, Teplizumab, AG019 - High Dose, AG019 - Low or High Dose
Study Phase: Phase 1/Phase 2
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
A Phase 2, Randomized, Parallel, Open-Label Comparator-Controlled Trial to Evaluate the Safety and Efficacy of LY3209590 in Study Participants With Type 1 Diabetes Mellitus Previously Treated With Multiple Daily Injection Therapy
Enrollment Status: Completed
Publish Date: October 27, 2022
Intervention Type: Drug
Study Drugs: LY3209590, Insulin Degludec
Study Phase: Phase 2
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors
An Open-label Therapeutic Efficacy Study of Tirosint (Levothyroxine Sodium) Capsules in Thyroidectomized Patients Taking Proton Pump Inhibitors
Enrollment Status: Completed
Publish Date: April 05, 2022
Intervention Type: Drug
Study Phase: Phase 4
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
An Open Label Study to Assess the Safety and Efficacy of COR-003 (Levoketoconazole) in the Treatment of Endogenous Cushing's Syndrome
Enrollment Status: Completed
Publish Date: April 19, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
A Prospective, Randomized, Double-Blind Comparison of LY900014 to Humalog in Adults With Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion
Enrollment Status: Completed
Publish Date: January 22, 2021
Intervention Type: Drug
Study Phase: Phase 3
View 9 Less Clinical Trials
Similar Doctors
Expertise in
42
conditions
Dr. John Carmichael
Endocrinology
Expertise in
42
conditions
Dr. John Carmichael
Endocrinology

USC Neurosurgeons Inc.

1520 San Pablo St Ste 3800, 
Los Angeles, CA 
 (61.7 miles away)
323-442-5100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

John Carmichael is an Endocrinologist in Los Angeles, California. Dr. Carmichael is highly rated in 42 conditions, according to our data. His top areas of expertise are Pituitary Tumor, Acromegaly, Hypothalamic Tumor, Endoscopic Transnasal Transsphenoidal Surgery, and Endoscopy.

Expertise in
37
conditions
Dr. Anthony Heaney
Endocrinology
Expertise in
37
conditions
Dr. Anthony Heaney
Endocrinology

Gonda (Goldschmied) Diabetes Center Santa Monica

2020 Santa Monica Blvd Ste 550, 
Santa Monica, CA 
 (47.9 miles away)
310-828-1050
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anthony Heaney is an Endocrinologist in Santa Monica, California. Dr. Heaney is highly rated in 37 conditions, according to our data. His top areas of expertise are Cushing's disease, Pituitary Tumor, Hypothalamic Tumor, Cushing's syndrome, and Endoscopic Transnasal Transsphenoidal Surgery.

Expertise in
12
conditions
Dr. Shlomo Melmed
Endocrinology
Expertise in
12
conditions
Dr. Shlomo Melmed
Endocrinology

Cedars-Sinai Pituitary Center

127 S San Vicente Blvd Ste A6600, 
Los Angeles, CA 
 (52.4 miles away)
310-423-2830
Languages Spoken:
English

Shlomo Melmed is an Endocrinologist in Los Angeles, California. Dr. Melmed is highly rated in 12 conditions, according to our data. His top areas of expertise are Acromegaly, Acromegaloid Facial Appearance Syndrome, Hypertrichosis-Acromegaloid Facial Appearance Syndrome, Pituitary Tumor, and Hormone Replacement Therapy (HRT).

Frequently Asked Questions about Dr. Ronald Chochinov

How do I make an appointment with Dr. Ronald Chochinov?

You can book an appointment with Dr. Ronald Chochinov by calling their office at 805-667-3909. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Ronald Chochinov a top-rated expert for Maturity Onset Diabetes of the Young?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Ronald Chochinov is classified as an Advanced expert for Maturity Onset Diabetes of the Young, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Ronald Chochinov specialize in?

While Dr. Ronald Chochinov is a Endocrinology, they have specific expertise in Maturity Onset Diabetes of the Young, Type 2 Diabetes (T2D), and Type 1 Diabetes (T1D). MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Endocrinology.

Does Dr. Ronald Chochinov accept my insurance?

Dr. Ronald Chochinov accepts most major insurance plans, including Humana. We recommend calling the office directly at 805-667-3909 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chochinov's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile